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PFirst Human Demonstration of Cardiac Stimulation
With Transcutaneous Ultrasound Energy Delivery
Implications for Wireless Pacing With Implantable Devices
Kathy L. Lee, MBBS, FACC,* Chu-Pak Lau, MD, FACC,* Hung-Fat Tse, MD, FACC,*
Debra S. Echt, MD, FACC,† David Heaven, MBCHB,‡ Warren Smith, MBCHB,‡
Margaret Hood, MBCHB‡
Hong Kong SAR, China; Sunnyvale, California; and Auckland, New Zealand
Objectives The purpose of this study was to evaluate the feasibility and safety of a novel technology that uses energy trans-
fer from an ultrasound transmitter to achieve cardiac stimulation without the use of a pacing lead in humans.
Background To overcome the limitations of pacemaker leads, a new technology enabling stimulation without the use of a
lead is desirable.
Methods A steerable bipolar electrophysiology catheter incorporating a receiver electrode into the tip and circuitry to con-
vert ultrasound energy to electrical energy was inserted transvenously into the heart. An ultrasound transmitting
transducer was placed on the chest wall with ultrasound gel. Ultrasound energy was amplitude-adjusted and
transmitted at 313 to 385 kHz. The output waveform of the receiver electrode was monitored while the trans-
mitter was moved on the chest wall to target the receiver. The ultrasound transmission amplitude was limited to
a mechanical index of 1.9, the maximum allowed for ultrasound imaging systems. Ultrasound-mediated pacing
with minimum voltage but consistent capture was obtained for 12 s.
Results Twenty-four patients (48  12 years) were tested during or after completion of clinical electrophysiology proce-
dures. A total of 80 pacing sites were tested (mean 3.3 sites/patient): 12 right atrial, 35 right ventricular, and
33 left ventricular (31 endocardial) sites. The transmit-to-receive distance was 11.3  3.2 cm (range 5.3 to 22.5
cm). Ultrasound-mediated pacing was achieved at all 80 test sites, with consistent capture at 77 sites. The me-
chanical index during pacing was 0.5  0.3 (range 0.1 to 1.5). The mean ultrasound-mediated capture threshold
was 1.01  0.64 V. There was no adverse event related to ultrasound pacing. No patient experienced discomfort
during pacing.
Conclusions The feasibility and safety of pacing usng ultrasound energy has been shown acutely. (J Am Coll Cardiol 2007;
50:877–83) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.081i
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lardiac pacemakers have been the established therapy for
atients with bradyarrhythmias for decades. Several recent
ndings have suggested a need for improving the standard
ransvenous leads used for permanent pacing. Firstly, clin-
cal trials have indicated that conventional right ventricle
RV) apical pacing may be deleterious (1–5). This has led to
he design and use of leads that can be implanted in other
elected locations (6). Secondly, randomized clinical trials
n cardiac resynchronization therapy (CRT) have shown its
linical benefits (7–9), especially when combined with an
rom the *Cardiology Division, Department of Medicine, University of Hong Kong,
ong Kong SAR, China; †EBR Systems, Inc., Sunnyvale, California; and the
Cardiology Division, Greenlane Cardiovascular Service, Auckland City Hospital,
uckland, New Zealand. Supported by a research grant from EBR Systems, Inc. Dr.
cht is employed by EBR Systems, Inc.c
Manuscript received October 16, 2006; revised manuscript received March 22,
007, accepted April 18, 2007.mplantable cardioverter-defibrillator (10). However, ap-
roximately 30% of patients who received CRT did not
ave a response, due in part to an unfavorable left ventric-
lar lead position (11,12). Access to the left ventricle (LV)
or CRT is achieved with the use of a pacing lead advanced
nto the coronary sinus (CS) and positioned in a coronary
ein (CV) branch. Implantation of this lead is technically
emanding and associated with a significant incidence of
ailure to implant, implantation in a suboptimal location,
nd complications including perforation or dissection of the
S (13,14). Thirdly, all pacing leads are associated with
omplications such as infection, fracture, and dislodgment.
xtraction of a failed lead that has been implanted for a long
ime is a high-risk procedure (15,16). With the new device
ystems that often require the implantation of multiple
eads, and with patients living longer, the incidence of lead
omplications becomes compounded over time. Therefore,
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Pacing With Ultrasound Energy in Humans August 28, 2007:877–83there is a clinical need to develop
a pacing system that reduces the
problems inherent with the pac-
ing leads. This study evaluates
the feasibility of a novel technol-
ogy that uses energy transfer
from an ultrasound transmitter
to a receiver electrode to achieve
cardiac stimulation without the
use of a pacing lead.
Methods
Patients. This 2-center study
complied with the provisions of
the Declaration of Helsinki, and
was approved by the Institutional
Review Board of the University
of Hong Kong and the Northern
X Regional Ethics Committee
administered by the New Zea-
and Ministry of Health. The study was conducted as a
onrandomized prospective feasibility study in patients
ndergoing a clinical electrophysiology study for standard
iagnostic and/or therapeutic indications. Patients who
ere 18 years or older and signed informed consent were
ligible to participate. Patients with any of the following
onditions were excluded: pregnancy, bacteremia, sepsis,
ctive systemic infection, myocardial infarction within 2
eeks, cardiac surgery within 2 weeks, percutaneous coro-
ary intervention within 2 weeks, unstable angina, acute
yocardial ischemia, intracardiac thrombus, severe valvular
eart disease, or clinical status unfit to undergo 30 to 60 min
f additional testing.
tudy equipment. The investigational stimulation system
EBR Systems, Inc., Sunnyvale, California) consisted of the
ollowing: 1) an ultrasound generator with an externally
pplied ultrasound transmission transducer; 2) a catheter
ncorporating a receiver electrode into the distal tip; and 3)
data collection and display system that included an
lectrophysiology recording system and a special instrument
o monitor and record electrical data for ultrasound trans-
ission and electrode output (Fig. 1).
The ultrasound generator and external transmitter pro-
uced a timed ultrasound field, coupled to the external
urface/chest of the patient using coupling gel (Intelect,
hatanooga Corp., Chattanooga, Tennessee), and option-
lly a gel pad (Aquaflex, Parker Laboratories, Fairfield, New
ersey). The transmitter was similar in appearance and
unction to an ultrasound imaging wand. The catheter
ontaining the receiver electrode was a custom 6-F steerable
lectrophysiology catheter (EBR Systems, Inc.). The receiv-
ng transducer and circuitry converted ultrasound energy to
lectrical energy and output the electrical energy to a pair of
ipolar electrodes. The cathode electrode was a 4-mm-long
Abbreviations
and Acronyms
CPK  creatine
phosphokinase
CRT  cardiac
resynchronization therapy
CS  coronary sinus
CV  coronary vein
ECG  electrocardiogram
ISPPA  spatial peak pulse
average intensity
ISPTA  spatial peak
temporal average intensity
LV  left ventricle
MI  mechanical index
RA  right atrium
RV  right ventricle
TI  thermal indexemispherical platinum/iridium electrode located at the tip, ind the anode was a 2-mm-long ring platinum/iridium
lectrode located 1 cm proximally. Transmitted ultrasound
aves passed into and through the patient’s body and
ntersected the receiver. The circuitry connected to the
eceiver converted the ultrasound waveform to an electrical
quare wave output delivered between the bipolar electrodes
o stimulate/pace the heart.
The ultrasound generator had a display screen and control
uttons to provide adjustable settings for ultrasound trans-
ission frequency, amplitude, transmit burst duration
pulse width), and transmit interval (cycle length). The
ltrasound transmission frequency to be used was optimally
djusted for each receiver electrode. The frequency selected
as determined based on water tank calibration testing
uring catheter construction. Selection of the ultrasound
ransmission amplitude was limited to an output corre-
ponding to a mechanical index (MI) of 1.9 in the heart.
his limit was selected because it is the maximum ampli-
ude typically used for ultrasound imaging systems.
Connections to the distal and proximal electrodes were
vailable in the catheter handle to allow for connection to an
lectrical pacing stimulator, an electrophysiology laboratory
ecording system (Maclab, GE Healthcare, Waukesha,
isconsin; EP MedSystems, West Berlin, New Jersey), or
Figure 1 Investigational Device System
Diagram of the investigational device system consisting of an ultrasound gener-
ator with an externally applied ultrasound transmit transducer, an intracardiac
catheter containing a receiver electrode incorporated into the distal tip, and
data collection instrumentation including an electrophysiology recording system
and storage oscilloscopes.nstrumentation for monitoring of the electrical output
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August 28, 2007:877–83 Pacing With Ultrasound Energy in Humansoltages on the electrodes during ultrasound-medicated
acing (Tektronix TDS 3014B, Beaverton, Oregon). Elec-
rical pacing was accomplished using a standard pro-
rammed stimulator (EP MedSystems). Recordings of in-
racardiac electrograms during intrinsic rhythms and that of
urface electrocardiogram (ECG) during electrical pacing
nd ultrasound-mediated pacing were obtained.
The receiver electrode output voltage was monitored in
eal time on 2 patient-isolated oscilloscopes; 1 was used to
ssist the operator of the transmitter on the chest wall in the
argeting of the receiver, and the other was used for data
ollection. The ultrasound generator was also connected to
he oscilloscopes to monitor ultrasound transmission.
tudy protocol. Prestudy safety procedures included a com-
lete cardiovascular examination, a 12-lead ECG, serum cre-
tine phosphokinase (CPK) with MB isoenzyme level, and a
ransthoracic echocardiogram to assess for intracardiac throm-
us, valvular disease, pericardial effusion, or other abnormali-
ies. After completion of the prestudy procedures, patients
nderwent testing in the clinical electrophysiology laboratory,
ither during or after completion of the clinical electrophysi-
logy procedure. The receiver electrode catheter was intro-
uced through the femoral vein and positioned in right atrium
RA), RV, or CV sites for both electrical and ultrasound-
ediated pacing. In patients who needed mapping of the left
eart, the catheter was positioned in the endocardial LV sites
y antegrade transeptal or retrograde transaortic approach, and
nfractionated heparin was used to maintain an activated
lotting time of 200 to 300 s throughout the procedure. The
election of stimulation sites for testing was at the discretion of
he attending physician.
The testing sequence for each site was as follows. The
ntracardiac electrograms from the catheter electrodes were
ecorded to confirm contact with viable myocardium. The
lectrical pacing threshold was obtained at a pacing
ycle length approximately 20% below the inherent cycle
ength at 0.5-ms pulse width. Twelve seconds of consistent
apture was recorded for documentation. The catheter elec-
rodes were then connected to the oscilloscopes to monitor the
oltage output during ultrasound-mediated pacing. The ultra-
ound transmitter was placed on an optimal position on the
hest wall. Pacing was accomplished by transcutaneous ultra-
ound bursts transmitted at the identical pacing cycle length
nd pulse width used for electrical pacing. Twelve seconds of
onsistent capture was recorded for documentation. After the
nitial 6 patients, the ultrasound-mediated pacing threshold
as also determined. The patients were queried regarding any
uditory or tactile sensations experienced during ultrasound
ransmission. The location of the transmitter was noted, and
he location of the receiver electrode was recorded on cine
mages. The catheter was repositioned to another site, and the
esting sequence was repeated.
After the study protocol, patients underwent postproce-
ure safety testing identical to that performed before the
rocedure and were assessed for potential adverse events. cata analysis. The primary study efficacy end point was
CG-documented stable ultrasound-mediated pacing at the
A, RV, and LV sites at which consistent electrical pacing was
chieved. The primary safety end point was freedom from
nvestigational device-related adverse events. Triggered oscil-
oscope recordings of 12 s of ultrasound-mediated pacing were
nalyzed for the minimum and the maximum output voltages
t the terminal portion of the pacing pulses. The minimum
eceiver electrode output voltage at the terminal portion of the
acing pulse was defined as the ultrasound-mediated pacing
hreshold. To directly compare the electrical pacing thresholds
easured as current (mA) with the ultrasound-mediated pac-
ng thresholds measured as voltage (V), a tissue impedance of
05 Ohms was used. This value was calculated using a model
or pacing leads (17), with adjustments made based on pre-
linical experimental measurements. Distances from the trans-
itter to the receiver were calculated by measuring the oscil-
oscope recording time delay from the onset of the ultrasound
ransmission burst to the onset of the receiver electrode output,
ultiplied by the speed of sound through the tissue (1.5
m/s) (18). Based on preprocedure and postprocedure water
ank calibration testing of the transmitter and receivers, and
orrections for tissue attenuation and distance, the MI at the
eceiver was calculated for each pacing site. Two energy
alculations were made, the ultrasound energy from the trans-
itter burst and the electrical energy output from the stimu-
ation pulse.
tatistical analysis. Data are presented as mean  SD. The
tudent paired t test was applied to compare electrical pacing
hresholds and minimum receiver electrode voltages. A prob-
bility value 0.05 was considered statistically significant.
esults
atient characteristics. Twenty-four patients, 12 male and
2 female, were evaluated with the investigational pacing
ystem. The patients’ ages were 48 12 years and weight was
5.2  15.7 kg (range 50 to 116 kg). The concurrent
lectrophysiology procedures performed were radiofrequency
blation for atrioventricular nodal re-entry tachycardia in 7
atients, atrioventricular re-entry tachycardia in 6 patients,
trial fibrillation in 2 patients, atrial flutter in 3 patients,
entricular tachycardia in 1 patient, both atrioventricular nodal
e-entry and ventricular tachycardia in 1 patient, and 4 patients
nderwent diagnostic electrophysiology studies alone. One
atient each had a history of aortic regurgitation, hypertrophic
ardiomyopathy, heart failure, hypertension, coronary artery
isease, and cerebrovascular accident. In the patient with heart
ailure, pre-existing atrioventricular conduction abnormality
as present, and a dual-chamber pacemaker (Philos,
iotronik, Berlin, Germany) had been implanted. No other
ardiovascular condition was present in 18 patients.
verall results. A total of 82 sites in the RA, RV, and LV
ere evaluated with the investigational pacing system. Two
ites were excluded for analysis because electrical pacing
apture was inconsistent. Of the 80 sites analyzed, 12 were
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Pacing With Ultrasound Energy in Humans August 28, 2007:877–83ithin the RA, 35 were within the RV, 31 were within the
V, and 2 were epicardial LV from the CV. A mean of 3.3
nd range of 2 sites to 6 sites were evaluated per patient.
lectrical and ultrasound-mediated pacing was performed
t a 460- to 600-ms pacing cycle length and a 0.5-ms pulse
idth. Ultrasound was transmitted at a mean frequency of
50  25 kHz, ranging from 313 to 385 kHz. A typical
ltrasound waveform is shown in Figure 2, and a typical
eceiver electrode output waveform is shown in Figure 3.
ltrasound-mediated pacing was successful at all 80 sites
ith consistent pacing capture achieved at 77 sites. There
as beat-to-beat variation in the receiver electrode output
oltage during pacing, and it ranged from a minimum of
.04  0.67 V to a maximum of 2.16  1.10 V. The
ltrasound-mediated pacing threshold, attempted at 59 sites
n 18 patients was 1.01  0.64 V. The electrical pacing
hreshold, obtained at 70 sites in 21 patients, was 1.60 
.12 mA. Assuming a tissue impedance of 605 Ohms, the
lectrical pacing threshold was 0.97  0.67, similar to the
ltrasound-mediated pacing threshold. The receiver elec-
rode output waveform from a storage oscilloscope is shown
n Figure 4. The MI at the site during ultrasound-mediated
acing was calculated to be 0.51  0.31 MI, ranging from
.12 to 1.50 MI. In the 18 patients in whom ultrasound-
ediated pacing thresholds were obtained, the MI at the
ite was calculated to be 0.45  0.30 MI. The mean
lectrical output energy per pacing pulse was 2.68  3.04
J, whereas the mean ultrasound energy burst was 12.86 
5.70 mJ. Figures 5A and 5B are examples of electrical and
ltrasound-mediated pacing from a midlateral LV site
howing that ECG morphology and blood pressure were
dentical. The results of pacing capture in each chamber are
hown in Table 1.
natomical considerations. Figure 6 shows 3 diagrams of
he human torso, with a 3  3 grid in which each square is
inches, superimposed over the chest wall region. Grids
abeled A, D, and G were centered over the sternum. As
ndicated by dots, the most commonly used chest location
or ultrasound transmission was within grid E or on the
order of grids D and E. This corresponded to the left
Figure 2 Ultrasound Burst
Recording of an ultrasound burst delivery at a
frequency of 350 kHz and a burst duration of 0.5 ms.arasternal region at the fifth intercostal space. However,
ot infrequently the transmitter position was directly over
he fourth rib, in the fourth intercostals space, or on the
ternum. The transmitter was angled up to 45° superiorly
rom perpendicular to target right-sided sites and up to 20°
o the left to target LV sites. The mean transmit-to-receive
Figure 3 Waveform Recording
Recording of a receiver electrode output waveform taken from a posteroseptal
right ventricular site. The voltage is 0.825 V at the leading edge and 1.29 V at
the trailing edge, and the pulse width is 0.5 ms.
Figure 4 Ultrasound-Mediated Pacing Threshold
Recording of the storage oscilloscope monitoring the receiver electrode output
capturing 12 s of ultrasound delivery in triggered mode. The top trace depicts
the ultrasound transmit marker and duration of 0.5 ms. The bottom trace
depicts 12 s of electrode output waveforms (20 superimposed waveforms).
Beat-to-beat variation in output voltage resulted in the appearance of a wide
band. The minimal voltage, recorded as the ultrasound-mediated pacing thresh-
old voltage, was measured at the lower boundary of the trailing edge of the
superimposed output waveforms. The maximum voltage was measured at the
upper boundary of the trailing edge of the superimposed output waveforms.
The transmitter-to-receiver distance was calculated from the transmit delay
from the onset of the ultrasound transmission to the onset of the electrode
output waveform.
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August 28, 2007:877–83 Pacing With Ultrasound Energy in Humansistance was 11.3  3.2 cm, ranging from 5.3 to 22.5 cm.
his measurement included traversing the 1-cm-thick gel
ad used for 39 of 80 sites to facilitate angulation of the
ransmitter. If the contribution of the gel pad thickness to
he distance measurements were eliminated, the mean
ransmit-to-receive distance was 10.7  3.08 cm.
The general locations of the pacing sites and pacing data for
ites in each of the RA, RV, and LV chambers are listed in
able 1. Results for each heart chamber were similar except
hat the distances to the RV sites were generally shorter than
hose to the RA and LV sites. The MI for ultrasound-
ediated pacing tended to be higher in the RA, and the mean
nergy efficiency tended to be lower. The apparent higher
lectrical pacing threshold in the LV is attributed to the 2
picardial sites accessed from the CS, which were 7 and 5 mA.
Figure 5 Ultrasound and Electrical Stimulation
Recordings obtained by the investigational catheter positioned at a midlateral
left ventricular site during (A) electrical pacing and (B) ultrasound-mediated
pacing. Tracing shown from top to bottom are surface electrocardiogram (ECG)
lead I, V1, V6, aortic blood pressure (ABP), electrical stimulation (E), and ultra-
sound transmission (US) marker channels.
lectrical and Ultrasound Pacing Parameters of All Cardiac Chamb
Table 1 Electrical and Ultrasound Pacing Parameters of All Ca
Cardiac Chambers Right Atrium
Number of sites and receiver locations 12
High septum (5)
Low septum (3)
Lateral (3)
Appendage (1)
Electrical pacing threshold (V)* 12 0.83 0.16
Minimum receiver electrode output (V) 5 0.66 0.21†
Maximum receiver electrode output (V) 12 1.95 0.65
Mechanical index 12 0.72 0.23
Transmitter-to-receiver distance (cm) 12 13.8 1.8
Electrical output energy per pacing pulse (J) 12 1.50 0.81
Ultrasound output energy per transmit burst (mJ) 12 26.60 17.36Assumes impedance of 605 Ohms. Values in remainder of table are presented as n,mean SD. †p NS (pahere were 3 sites in which ultrasound-mediated pacing was
nconsistent, 2 were in the RA on the lateral wall and 1 was an
picardial LV site in the posterior CV.
afety results. The results of safety testing performed
efore and after the research protocol did not reveal any
bnormality attributable to the investigational devices. One
atient experienced a procedure-related adverse event of a
alse aneurysm of the femoral artery that was treated
uccessfully with thrombin injection. Nine patients had
xpected minimal elevations of CPK and creatine
inase-MB level attributable to the concomitant clinical
blation procedure. No patient experienced discomfort dur-
ng ultrasound-mediated pacing. Only 1 patient noted a
ery mild pressure sensation for 1 of 4 sites tested.
In addition to MI values, thermal index (TI) values and
tandard ultrasound indices of intensity, spatial peak pulse
verage intensity (ISPPA), and spatial peak temporal aver-
ge intensity (ISPTA) were calculated. The average peak
I, located 2.5 to 3.0 cm from the transmitter surface, was
.0326 (range 0.001 to 0.144) for soft tissue and 0.855
range 0.03 to 4.14) for bone. The average ISPPA was 22.7
/cm2 (range 0.74 to 112 W/cm2), and the average ISPTA
as 19.23 mW/cm2 (range 0.62 to 93.1 mW/cm2). Both
arameters were well below the FDA preamendment diag-
ostic ultrasound acoustic output intensity guideline recom-
endations that ISPPA should not exceed 190 W/cm2 and
SPTA should not exceed 430 mW/cm2 (19).
iscussion
o the best of our knowledge, this is the first demonstration in
umans of using energy transfer to achieve cardiac stimulation
ithout the use of leads. Acute success of this novel technology
sing ultrasound energy transmission through the body pro-
ides evidence for the feasibility of developing implantable
ardiac pacemaker systems without pacing leads.
afety considerations. To assess safety before performing
his study in patients, preclinical studies were performed in
valuated
Chambers Evaluated
Right Ventricle Left Ventricle All
35 33 80
Apex (12)
Outflow tract (9)
Septum (6)
Posterior (4)
Anterior (2)
Lateral (2)
Endocardial:
Lateral (15)
Posterior (11)
Septum (4)
Apex (1)
Epicardial:
Posterior (2)
All
31 0.81 0.51 27 1.22 0.89 70 0.970 0.67
26 1.00 0.47† 27 1.08 0.80† 59 1.01 0.64†
35 2.17 0.96 33 2.23 1.35 80 2.16 1.10
35 0.51 0.32 33 0.46 0.28 80 0.51 0.31
35 8.5 1.9 33 13.1 2.3 80 11.3 3.2
35 2.63 2.22 33 3.11 4.06 80 2.68 3.04
35 7.29 9.26 33 14.19 7.74 80 12.86 15.70ers E
rdiacired t test) comparing electrical pacing voltage threshold andminimum receiver electrode voltage.
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Pacing With Ultrasound Energy in Humans August 28, 2007:877–83animals (5 treated and 1 sham) (20). Ultrasound energy
as applied at intensities and durations anticipated to
xceed those used in human testing. Histopathological
valuation performed from specimens of the heart, lungs,
nd chest wall showed no evidence of bioeffects attributable
o ultrasound transmission.
echnical advantages. The use of ultrasound energy pro-
ides several advantages over other forms of remote energy
ransfer. For example, conventional pacemakers are vulner-
ble to interference from the use of electromagnetic energy
ources but not ultrasound transmission. One of our study
atients was pacing-dependent, and pacemaker function
uring transmission of ultrasound energy was normal.
At the lower ultrasound frequencies used in this study, in
he range of 350 kHz, there is relatively little attenuation
ver distance. Water tank bench testing showed no signif-
cant change in ultrasound intensities at the range of
istances encountered in this study. Consistent pacing was
chieved at various transmission distances of up to 22.5 cm.
his is in contrast to the ultrasound frequencies used for
ransthoracic ultrasound imaging or intracardiac ultrasound
maging applications, using the frequency range of 2 to 5
Hz or 25 to 30 MHz correspondingly, where attenuation
imits beam penetration to within approximately 10 or 1 cm
espectively. The lower frequencies used in this study also
nable penetration through bone with only minor attenua-
ion of about 3 dB (18), which enlarges the area of the
ransthoracic ultrasound window. This allows better design
f the transducer that improves the efficiency of energy
onversion by enhancing the focus of the ultrasound beam.
echnical challenges. Ultrasound-mediated cardiac stim-
lation was shown at all 80 sites tested, and consistent
acing was shown in 77 sites. The inability to pace consis-
ently at 3 sites is partly attributable to the protocol
imitation of a maximum MI. This restriction was imposed
o voluntarily conform to levels used for commercial ultra-
ound imaging systems (19). It is likely that higher ultra-
ound amplitudes would have resulted in consistent capture
Figure 6 Ultrasound Window
Drawings of the human torso with a grid representing the window used for transm
targeting a site in the (A) RA, (B) RV, and (C) LV is shown as a dot. LV  left vent these sites. Another issue was substantial beat-to-beat mariation observed in the receiver electrode output. As
hown in Table 1 and Figure 4, the receiver electrode output
aximum voltages averaged 2-fold higher than the mini-
um voltages. For the 3 sites with inconsistent pacing,
acing capture only occurred on beats having receiver
lectrode output voltages above the minimum voltage.
onsistent pacing, therefore, was achievable only if all
timulation pulses were above the minimum receiver elec-
rode output voltage threshold. Several factors contribute to
he beat-to-beat variability in output voltages. One factor is
hat ultrasound energy in the transmitted beam in the direct
ath of the lungs is reflected, some into the direct path of
he receivers. Depending on phase shifts, the receiver
lectrode output amplitude at any point in time may be
nhanced or reduced. This phenomena can be identified
oth by amplitude variations within an individual receiver
lectrode output waveform pulse as well as between pulses.
ecause the velocity of sound in bone is different from that
n other tissue, there are also refractive effects from the ribs.
ther factors include variations caused by cardiac and
espiratory motion, and to a lesser extent in this protocol, to
ody movement and position. The angle of the receiver in
elationship to the angle of the transmitted ultrasound beam
aried with motion, causing further variation in energy
eception depending on the angulation during the ultra-
ound pulse. Also, the ultrasound beam profile is not
ompletely homogeneous across the beam. Finally, attenu-
tion of the ultrasound beam is known to occur with
istance because of tissue absorption. For all of these
easons, the receiver may be exposed to differing amplitudes
f ultrasound energy during the pacing attempts. A focus of
uture studies will be to elucidate the mechanisms of
eat-to-beat variability.
This new technology is associated with inherent ineffi-
iencies as compared with direct electrical stimulation. The
fficiency of energy conversion, as calculated from the
eceiver electrode output energy compared with the trans-
itted energy (Table 1), was only 0.063%. No attempt was
of ultrasound energy over the chest wall. The central position of the transmitter
RA  right atrium; RV  right ventricle.ission
tricle;ade to optimize the energy efficiency of the system used in
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August 28, 2007:877–83 Pacing With Ultrasound Energy in Humanshese studies. Electrical energy is expended to initially
enerate the ultrasound transmission, ultrasound energy
isperses across its beam, the ultrasound energy attenuates
ver distance because of absorption into tissue, and finally
he energy must be transduced back into electrical energy for
acing. There are opportunities for substantial improvement
n these areas, especially the transmitter beam. The trans-
itter beam used in the study was broad and unfocused; the
eceiver area was only 0.0045% of the beam area. Dynamic
ocusing of the beam could markedly increase efficiency.
ith today’s battery technology and optimization in this
ltrasound system, it is likely that a single-chamber pace-
aker with reasonable longevity is feasible.
tudy limitations. The majority of the patients had struc-
urally normal hearts. There would likely be differences in
esults in patients with a dilated heart and abnormal cardiac
natomy. Patients were tested in the supine position only.
he effects caused by cardiac contraction and respiration
otion were observed, but those caused by changes in body
osition were not evaluated. Because pacing was evaluated
cutely, the conclusions cannot be extrapolated to the
xtended period of pacing.
uture applications. The technology tested acutely in this
tudy is currently under development as a leadless implant-
ble system for chronic clinical use. It will be composed of
n ultrasound pulse generator, receiver electrode(s), delivery
atheter(s), and programmer/pacing system analyzer. The
mplantation of a relatively small receiver electrode in the
eart will entail the percutaneous insertion of a preloaded
elivery catheter via a femoral artery or vein. The delivery
atheter will be advanced to a selected endocardial site. The
eceiver electrode will be activated to assess pacing from that
ite, and the receiver electrode will be deployed by active
xation for implantation. The pulse generator device will
nclude an ultrasound transmitter, cardiac signal processing
ircuits, pacing control logic, and a battery. It will be
mplanted subcutaneously in the left precordial chest region.
he precordial location will be selected to optimize ultra-
ound energy transmission to the implanted receiver(s). The
rogrammer/pacing system analyzer will provide tools for
acing assessment for implant procedure and follow-up.
onclusions
he feasibility and safety of cardiac stimulation using a
emote energy source, without pain or discomfort, has been
hown in the short term in patients for the first time. This
ew technology using ultrasound energy has the potential
or application to permanent pacing systems. It has the
dvantages of avoiding the complications inherent to pacing
eads and accessibility to different locations within various
ardiac chambers enabling selective-site and multisite pac-
ng. The development of implantable receiver electrodes
olds hope for a new paradigm in pacemaker therapy.eprint requests and correspondence: Dr. Kathy L. Lee, Car-
iology Division, Department of Medicine, Queen Mary Hospital,
02, Pokfulam Road, Hong Kong SAR, China. E-mail:
lflee@hku.hk.
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